CD26 in T-cell lymphomas: a potential clinical role?
T-cell non-Hodgkin's lymphomas are a heterogeneous group of diseases that differ markedly in terms of their clinical behavior and prognosis. In recently developed classification systems, the sites of initial disease presentation assume a more prominent role in subgroup delineation. CD26, a structure with an integral role in human T-cell function that serves as the binding protein to adenosine deaminase, has been identified recently as a potential marker for certain aggressive T-cell lymphomas. To translate our knowledge of the basic biology of CD26/adenosine deaminase into clinical practice and to develop specific treatment for T-cell lymphomas based on CD26 expression, we, at M. D. Anderson Cancer Center, have initiated a phase II trial. This trial will evaluate the effect of pentostatin (Nipent), a potent adenosine deaminase inhibitor with known efficacy against T-cell malignancies, on relapsed/refractory T-cell lymphomas in relation to CD26 expression.
Verstovsek
S
S
Department of Lymphoma/Myeloma, University of Texas, M. D. Anderson Cancer Center, Houston, USA.
Cabanillas
F
F
Dang
N H
NH
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D017322:Clinical Trials, Phase II as Topic; D018819:Dipeptidyl Peptidase 4 / Q000096:biosynthesis*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000145:classification / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D015649:Pentostatin / Q000627:therapeutic use; D011379:Prognosis; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D015649:Pentostatin; D018819:Dipeptidyl Peptidase 4